Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UTP25 small subunit processome component (UTP25)
- Target
- UTP25
- Molecular classification
- Pseudoenzyme (pseudohelicase), DEAD-box RNA helicase-like protein, Ribosome assembly factor, Small subunit (SSU) processome component, Nucleolar protein, P-loop nucleoside triphosphate hydrolase-like domain
01
Overview
UTP25 small subunit processome component (UTP25) is a highly conserved nucleolar protein essential for ribosomal small subunit (SSU) biogenesis[5][1]. It is classed as a pseudoenzyme, showing structural similarity to DEAD-box RNA helicases but lacking key catalytic motifs, making it unable to function as a true helicase[1][2]. UTP25 is involved in pre-rRNA processing, binding to U3 snoRNA and rRNA, and serves as a scaffold or co-factor within the SSU processome that assembles the small ribosomal subunit. It is vital for embryonic development, especially of digestive organs, and plays a regulatory role in the p53 pathway, influencing cell survival and growth[5][1][3]. UTP25 is expressed in the nucleolus and interacts with other proteins involved in ribosome assembly but is not targeted by any current therapeutics.
- Other names
- U3 small nucleolar RNA-associated protein 25 homologC1orf107DEF (Digestive organ expansion factor homolog)DIEXFDJ434O14.5MGC29875lily liver (lly)wu:fc51g08wu:fi05f05
02
Mechanism of action
Not applicable. No known drugs target UTP25.
03
Biological functions
Pre-ribosomal RNA processing (essential for maturation of 18S rRNA in ribosome biogenesis)Binding to U3 snoRNA and rRNAProtein localization to nucleolusRegulation of the p53 pathway and degradation of p53Embryonic organ development and expansion of digestive organsCell protein destabilization and catabolic processesSympathetic neuronal developmentProtein scaffold/co-factor role in SSU processome assembly
04
Disease associations
Epidermolysis bullosa simplex localized type (association, not causality)Combined oxidative phosphorylation deficiency 1 (association)Cancer (via influence on p53 pathway, potential implications for mutation effect prediction)Other: Roles in ribosome biogenesis link UTP25 indirectly to diseases involving ribosomopathies or disorders of embryonic organ development, but no direct causative links
05
Safety considerations
None defined for drug targeting, since UTP25 is not a therapeutic targetMutation or disruption can impair ribosome biogenesis and organ development, which could be deleterious in model organisms
06
Biomarkers
None established for patient selection or efficacy monitoring.UTP25 expression or mutation status may be investigated for research, especially regarding embryonic development or ribosome biogenesis, but not used in clinical practice
Beyond the preview
Go deeper on UTP25 small subunit processome component (UTP25).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UTP25 small subunit processome component (UTP25).